Flunisolide hemihydrate 

Flunisolide hemihydrate is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide hemihydrate can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation^[1][2].

Flunisolide hemihydrate (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation^[1].
Flunisolide hemihydrate (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated from mild to moderate asthmatics), and induces sputum eosinophil apoptosis^[2].
Flunisolide hemihydrate (0.1-10 µM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells^[3].
Flunisolide hemihydrate (115 µM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Flunisolide hemihydrate (Intranasal administration, 0.3-10 µg/mouse, daily, from days 21–27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice^[1].
Flunisolide hemihydrate (Intranasal administration, 0.3-10 µg/mouse, daily, from days 21–27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

443.51

C₂₄H₃₃FO₇

77326-96-6

C[C@@]12[C@@]3(C(CO)=O)[C@@](OC(C)(O3)C)([H])C[C@@]1([H])[C@]4([H])C[C@H](F)C5=CC(C=C[C@]5(C)[C@@]4([H])[C@@H](O)C2)=O.[1/2].O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tatiana Paula Teixeira Ferreira, et al. Intranasal Flunisolide Suppresses Pathological Alterations Caused by Silica Particles in the Lungs of Mice. Front Endocrinol (Lausanne). 2020 Jun 17;11:388.  [Content Brief]

  [2]. M Profita, et al. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy. 2004 Sep;59(9):927-32.  [Content Brief]

  [3]. S Boero, et al. Modulation by flunisolide of tumor necrosis factor-alpha-induced stimulation of airway epithelial cell activities related to eosinophil inflammation. J Asthma. 2010 May;47(4):381-7.  [Content Brief]

  [4]. B I Florea, et al. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br J Pharmacol. 2001 Dec;134(7):1555-63.  [Content Brief]